SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:1496e9fa-e58a-487c-8c18-23b301a5ba5e"
 

Search: onr:"swepub:oai:lup.lub.lu.se:1496e9fa-e58a-487c-8c18-23b301a5ba5e" > Societal challenges...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Salgado, RobertoUniversity of Antwerp (author)

Societal challenges of precision medicine : Bringing order to chaos

  • Article/chapterEnglish2017

Publisher, publication year, extent ...

  • Elsevier BV,2017

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:1496e9fa-e58a-487c-8c18-23b301a5ba5e
  • https://lup.lub.lu.se/record/1496e9fa-e58a-487c-8c18-23b301a5ba5eURI
  • https://doi.org/10.1016/j.ejca.2017.07.028DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:136665509URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • The increasing number of drugs targeting specific proteins implicated in tumourigenesis and the commercial promotion of relatively affordable genome-wide analyses has led to an increasing expectation among patients with cancer that they can now receive effective personalised treatment based on the often complex genomic signature of their tumour. For such approaches to work in routine practice, the development of correspondingly complex biomarker assays through an appropriate and rigorous regulatory framework will be required. It is becoming increasingly evident that a re-engineering of clinical research is necessary so that regulatory considerations and procedures facilitate the efficient translation of these required biomarker assays from the discovery setting through to clinical application. This article discusses the practical requirements and challenges of developing such new precision medicine strategies, based on leveraging complex genomic profiles, as discussed at the Innovation and Biomarkers in Cancer Drug Development meeting (8th–9th September 2016, Brussels, Belgium).

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Moore, HelenNational Cancer Institute, USA (author)
  • Martens, John W MErasmus University Medical Center (author)
  • Lively, TracyNational Cancer Institute, USA (author)
  • Malik, ShakunNational Cancer Institute, USA (author)
  • McDermott, UltanWellcome Trust Sanger Institute (author)
  • Michiels, StefanUniversity of Paris-Saclay (author)
  • Moscow, Jeffrey A.National Cancer Institute, USA (author)
  • Tejpar, SabineUniversity Hospitals Leuven (author)
  • McKee, TawnyaNational Cancer Institute, USA (author)
  • Lacombe, DenisEuropean Organisation for Research and Treatment of Cancer (author)
  • Becker, RobertUnited States Food and Drug Administration (author)
  • Beer, PhilipWellcome Trust Sanger Institute (author)
  • Bergh, JonasKarolinska University Hospital (author)
  • Bogaerts, JanEuropean Organisation for Research and Treatment of Cancer (author)
  • Dovedi, SimonMedImmune Limited, Cambridge (author)
  • Fojo, Antonio T.Columbia University (author)
  • Gerstung, MoritzEuropean Bioinformatics Institute (author)
  • Golfinopoulos, VassilisEuropean Organisation for Research and Treatment of Cancer (author)
  • Hewitt, Stephen M.National Cancer Institute, USA (author)
  • Hochhauser, DanielUCL Cancer Institute (author)
  • Juhl, HartmutIndivumed GmbH (author)
  • Kinders, RobertNational Cancer Institute at Frederick (author)
  • Lillie, ThomasMerck Sharp & Dohme Limited, UK (author)
  • Herbert, Kim LyerlyDuke University (author)
  • Maheswaran, ShyamalaMassachusetts General Hospital (author)
  • Mesri, MehdiNational Cancer Institute, USA (author)
  • Nagai, SumimasaPharmaceuticals and Medical Devices Agency (author)
  • Norstedt, IreneEuropean Commission (author)
  • O'Connor, DanielMedicines & Healthcare Products Regulatory Agency (MHRA) (author)
  • Oliver, KathyInternational Brain Tumour Alliance (IBTA) (author)
  • Oyen, Wim J.G.Institute of Cancer Research London (author)
  • Pignatti, FrancescoEuropean Medicines Agency (EMA) (author)
  • Polley, EricMayo Clinic Minnesota (author)
  • Rosenfeld, NitzanUniversity of Cambridge (author)
  • Schellens, JanAntoni Van Leeuwenhoek Hospital (author)
  • Schilsky, RichardAmerican Society of Clinical Oncology (author)
  • Schneider, ErasmusWadsworth Center for Laboratories and Research (author)
  • Senderowicz, AdrianCerulean Pharma Inc. (author)
  • Tenhunen, OlliFinnish Medicines Agency (author)
  • van Dongen, AugustinusAmsterdam UMC - Vrije Universiteit Amsterdam (author)
  • Vietz, ChristineFoundation Medicine, Inc. (author)
  • Wilking, NilsLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)med-nlw (author)
  • University of AntwerpNational Cancer Institute, USA (creator_code:org_t)

Related titles

  • In:European Journal of Cancer: Elsevier BV84, s. 325-3340959-80491879-0852

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view